Tumors with loss of ATRX have been shown to a great extent to harbor a sharper hypersignal intensity area margin and a higher ADC value of the T2 hyperintense lesion compared with tumors that contain wild-type ATRX, which suggests a better prognosis in patients with this GBM subtype (70). The gene discussed is ATRX; the disease is glioblastoma.